Opko Health price target raised to $5 from $4 at Piper Sandler

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Opko Health to $5 from $4 and keeps an Overweight rating on the shares. The FDA recently approved once-weekly Ngenla to treat pediatric growth hormone deficiency, triggering a $90M milestone and bringing Opko’s pro forma cash to $198M, the analyst tells investors in a research note.